Reducing HIV transmission when using hormonal contraceptives

March 21, 2018 by Thomas L. Cherpes, The Conversation
Mice are ‘humanized’ by an injection of human blood cells. This allows mice to help define how human immune cells react to various treatments and infections. Credit: Levorian, CC BY-SA

More women are affected by human immunodeficiency virus (HIV) than any other life-threatening infectious agent. This makes it crucial to identify all factors increasing the risk of HIV infection.

One risk factor may be injectable hormonal contraceptives. Worldwide, these drugs are used by 41 million women and about 2 million in the United States. The most popular is Depo-Provera.

While indicate women using injectable hormonal contraceptives are more susceptible to HIV, no study has proven they cause women to acquire HIV infection. This lack of definitive proof makes it difficult to develop usage guidelines for these drugs.

My lab studies genital immune responses in humans and animal models. In experiments with female , we uncovered how Depo-Provera may promote HIV transmission and a way to potentially avoid this effect.

HIV and unplanned pregnancy

Based on its link to HIV transmission, last year the World Health Organization revised its recommendation for Depo-Provera, changing its classification from "use without restriction" to "benefits outweigh theoretical or proven risks."

This change was designed to ensure women are informed by health care providers of the potential risks associated with Depo-Provera.

However, the WHO also advised that clinicians continue providing unrestricted access to Depo-Provera.

Our incomplete understanding of Depo-Provera's effects thus creates a public health dilemma. On one hand, women must be informed of the data that indicate injectable contraceptives increase their HIV risk. On the other, Africa and other areas with high burdens of HIV disease have high infant and maternal mortality rates and great need for effective contraception.

Moreover, some believe the links seen between Depo-Provera and HIV are behavioral, not biological. In other words, women using hormonal contraception acquire HIV more often simply because they have more unprotected sex.

These uncertainties suggested new research strategies were needed to understand relationships between Depo-Provera and HIV transmission.

Exploring the connection in mice

To define the effects of Depo-Provera on HIV transmission, my lab injected with human blood cells, a process called "humanizing." These humanized mice can be used to examine how specific treatments alter human immune cell function and to study HIV and other human pathogens.

We found that treating humanized mice with Depo-Provera made their genital tissue more permeable to immune cells called leukocytes. This increase in permeability likewise made it easier for HIV-infected leukocytes to invade genital tissue and cause systemic infection.

Our findings thus provide plausibility for the suspected increased risk of HIV in women using Depo-Provera. Supporting the relevance of our work for women, animal models and clinical studies have indicated that the HIV-infected leukocytes we used are an important cause of HIV transmission in humans.

Looking to mice for solutions

However, we also used mice to show that increases in tissue permeability and HIV transmission caused by Depo-Provera were eliminated in mice treated with Depo-Provera and Premarin, a vaginal estrogen cream prescribed to menopausal women.

This implies contraceptives releasing progestin and estrogen have the potential to avoid the increases in HIV susceptibility caused by Depo-Provera alone.

While intriguing, this conclusion is speculative, as mice do not model all changes seen in the genital tracts of women using Depo-Provera.

Therefore, before contraceptives that contain progestin and estrogen are adopted as a HIV prevention strategy, it will be crucial to confirm our results in nonhuman primates and clinical trials. Importantly, clinical studies testing this strategy can start immediately, as contraception releasing both estrogen and progestin is already commercially available.

As evidence linking injectable contraceptives with HIV continues to accumulate, this research will help identify contraceptive strategies less likely to put women at risk for HIV infection. Completing these studies will ultimately help women make more informed contraceptive choices.

Explore further: The search for answers to hormonal contraception's role in HIV infection

Related Stories

The search for answers to hormonal contraception's role in HIV infection

July 22, 2016
About 75% of HIV-infected people in sub-Saharan African between the ages of 15 and 24 are women. Many factors play a role in this gender imbalance. These include gender-based social disparity and a high prevalence of intergenerational ...

Study in Lancet finds use of hormonal contraception doubles HIV risk

October 3, 2011
Women using hormonal contraception --such as a birth control pill or a shot like Depo-Provera – are at double the risk of acquiring HIV, and HIV-infected women who use hormonal contraception have twice the risk of transmitting ...

Condom use among high school girls using long-acting contraception

March 14, 2016
High school girls who used intrauterine devices and implants for long-acting reversible contraception were less likely to also use condoms compared with girls who used oral contraceptives, according to an article published ...

Contraceptive use up for women with congenital heart disease

March 13, 2017
(HealthDay)—Women with congenital heart disease (CHD) use a spectrum of contraceptive methods, with barrier methods and oral contraception (OC) preferred, according to a study published in the March 15 issue of The American ...

Recommended for you

Study shows how HIV is shielded from immune attack

July 10, 2018
Scientists from UNSW Sydney and the UK have discovered that the human immunodeficiency virus (HIV) hijacks a small molecule from the host cell to protect itself from being destroyed by the host's immune system.

Out-of-pocket costs put HIV prevention drug out of reach for many at risk

July 4, 2018
Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections. But the officials are hitting roadblocks—the drug's price tag, which ...

New simulation tool predicts how well HIV-prophylaxis will work

June 14, 2018
A new mathematical simulation approach predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, which help prevent HIV infection. The framework, presented in PLOS Computational Biology by Sulav Duwal ...

Many at risk for HIV despite lifesaving pill

June 11, 2018
Multiple barriers may stop high-risk individuals from accessing an HIV drug that can reduce the subsequent risk of infection, according to a new University of Michigan study.

Active HIV in large white blood cells may drive cognitive impairment in infected mice

June 7, 2018
Macrophages, large white blood cells that engulf and destroy potential pathogens, harbor active viral reserves that appear to play a key role in impaired learning and memory in mice infected with a rodent version of HIV. ...

HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains

June 4, 2018
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.